Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;22(12):2272-2289.
doi: 10.1002/ejhf.2029. Epub 2020 Nov 12.

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Rudolf A de Boer  1 , Jean-Sébastien Hulot  2   3 , Carlo Gabriele Tocchetti  4 , Joseph Pierre Aboumsallem  1 , Pietro Ameri  5   6 , Stefan D Anker  7 , Johann Bauersachs  8 , Edoardo Bertero  9 , Andrew J S Coats  10 , Jelena Čelutkienė  11 , Ovidiu Chioncel  12 , Pierre Dodion  13 , Thomas Eschenhagen  14   15 , Dimitrios Farmakis  16   17 , Antoni Bayes-Genis  18   19   20 , Dirk Jäger  21 , Ewa A Jankowska  22 , Richard N Kitsis  23 , Suma H Konety  24 , James Larkin  25 , Lorenz Lehmann  26   27   28 , Daniel J Lenihan  29 , Christoph Maack  9 , Javid J Moslehi  30 , Oliver J Müller  31   32 , Patrycja Nowak-Sliwinska  33   34 , Massimo Francesco Piepoli  35 , Piotr Ponikowski  22 , Radek Pudil  36 , Peter P Rainer  37 , Frank Ruschitzka  38 , Douglas Sawyer  39 , Petar M Seferovic  40 , Thomas Suter  41 , Thomas Thum  42 , Peter van der Meer  1 , Linda W Van Laake  43 , Stephan von Haehling  44   45 , Stephane Heymans  46   47 , Alexander R Lyon  48 , Johannes Backs  49   27
Affiliations

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Rudolf A de Boer et al. Eur J Heart Fail. 2020 Dec.

Abstract

The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time.

Keywords: Angiogenesis; Cancer; Cardio-oncology; Cardiotoxicity; Clonal haematopoiesis; Extracellular matrix; Heart failure; Inflammation; Metabolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graphic illustration showing somatic mutations in haematopoietic stem cells as a common path for cancer (leukaemia) and cardiovascular disease. 50 In individuals with a single somatic mutation, the development of leukaemia requires additional mutations. These individuals are exposed to a higher risk of developing heart failure (HF) and atherosclerosis. This may be due to the overproduction of pro‐inflammatory cytokines by cells with somatic mutations. Illustration elements are from Smart Servier Medical Art.
Figure 2
Figure 2
Representative scanning electron and photomicrographs of the three‐dimensional arrangement of left ventricular extracellular matrix in the human heart. Samples are from individuals with infiltrative (amyloidosis), non‐ischaemic, and ischaemic cardiomyopathy (CM) compared to an unused non‐failing donor heart. The top two panels show the matrix in cross‐section, with a typical honey‐comb structure that is notably less fine and organized, but with distinct patterns, in CM compared to non‐CM myocardium. H&E stained sections from the same hearts are shown in the bottom row for comparison. Bars = 40 mm (top row) and 2 mm (middle row). Tissue is courtesy of the Vanderbilt Cardiovascular Institute Biobank and images are shown with permission from Cristi Galindo and Sean Lenihan.
Figure 3
Figure 3
Graphical presentation that summarizes the proposed common pathways involved in the development and progression of cancer and heart failure (HF). CV, cardiovascular. Illustration elements are from Smart Servier Medical Art.
Figure 4
Figure 4
Roadmap that represents the key steps needed to guide and improve future clinical and pre‐clinical research and increase the collaboration between cardiologists and oncologists. Illustration elements are from Smart Servier Medical Art.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJ. Declining risk of sudden death in heart failure. N Engl J Med 2017;377:41–51. - PubMed
    1. Moliner P, Lupon J, de Antonio M, Domingo M, Santiago‐Vacas E, Zamora E, Cediel G, Santesmases J, Díez‐Quevedo C, Troya MI, Boldó M, Altmir S, Alonso N, González B, Núñez J, Bayes‐Genis A. Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. Eur J Heart Fail 2019;21:1259–1266. - PubMed
    1. Conrad N, Judge A, Canoy D, Tran J, Pinho‐Gomes AC, Millett ER, Salimi‐Khorshidi G, Cleland JG, McMurray JJ, Rahimi K. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiol 2019;4:1102–1111. - PMC - PubMed
    1. Meijers WC, Maglione M, Bakker SJ, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HH, de Boer RA. Heart failure stimulates tumor growth by circulating factors. Circulation 2018;138:678–691. - PubMed
    1. Pfeffer TJ, Schlothauer S, Pietzsch S, Schaufelberger M, Auber B, Ricke‐Hoch M, List MS, Berliner D, Moulig V, König T, Arany Z, Sliwa K, Bauersachs J, Hilfiker‐Kleiner D. Increased cancer prevalence in peripartum cardiomyopathy. JACC CardioOncol 2019;1:196–205. - PMC - PubMed

Publication types